• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中东欧和波罗的海地区的心力衰竭护理:现状、障碍和改善途径。

Heart failure care in the Central and Eastern Europe and Baltic region: status, barriers, and routes to improvement.

机构信息

Emergency Institute for Cardiovascular Diseases 'Prof. Dr. C.C. Iliescu', Bucharest, Romania.

Carol Davila University of Medicine, Bucharest, Romania.

出版信息

ESC Heart Fail. 2024 Aug;11(4):1861-1874. doi: 10.1002/ehf2.14687. Epub 2024 Mar 22.

DOI:10.1002/ehf2.14687
PMID:38520086
原文链接:
https://pmc.ncbi.nlm.nih.gov/articles/PMC11287314/
Abstract

Despite improvements over recent years, morbidity and mortality associated with heart failure (HF) are higher in countries in the Central and Eastern Europe and Baltic region than in Western Europe. With the goal of improving the standard of HF care and patient outcomes in the Central and Eastern Europe and Baltic region, this review aimed to identify the main barriers to optimal HF care and potential areas for improvement. This information was used to suggest methods to improve HF management and decrease the burden of HF in the region that can be implemented at the national and regional levels. We performed a literature search to collect information about HF epidemiology in 11 countries in the region (Bulgaria, Croatia, Czechia, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Serbia, and Slovenia). The prevalence of HF in the region was 1.6-4.7%, and incidence was 3.1-6.0 per 1000 person-years. Owing to the scarcity of published data on HF management in these countries, we also collected insights on local HF care and management practices via two surveys of 11 HF experts representing the 11 countries. Based on the combined results of the literature review and surveys, we created national HF care and management profiles for each country and developed a common patient pathway for HF for the region. We identified five main barriers to optimal HF care: (i) lack of epidemiological data, (ii) low awareness of HF, (iii) lack of national HF strategies, (iv) infrastructure and system gaps, and (v) poor access to novel HF treatments. To overcome these barriers, we propose the following routes to improvement: (i) establish regional and national prospective HF registries for the systematic collection of epidemiological data; (ii) establish education campaigns for the public, patients, caregivers, and healthcare professionals; (iii) establish formal HF strategies to set clear and measurable policy goals and support budget planning; (iv) improve access to quality-of-care centres, multidisciplinary care teams, diagnostic tests, and telemedicine/telemonitoring; and (v) establish national treatment monitoring programmes to develop policies that ensure that adequate proportions of healthcare budgets are reserved for novel therapies. These routes to improvement represent a first step towards improving outcomes in patients with HF in the Central and Eastern Europe and Baltic region by decreasing disparities in HF care within the region and between the region and Western Europe.

摘要

尽管近年来有所改善,但与心力衰竭(HF)相关的发病率和死亡率在中东欧和波罗的海地区国家高于西欧国家。为了提高中东欧和波罗的海地区的 HF 护理标准和患者预后,本综述旨在确定优化 HF 护理的主要障碍以及潜在的改进领域。这些信息被用于提出可以在国家和地区层面实施的改善 HF 管理和减轻该地区 HF 负担的方法。我们进行了文献检索,以收集该地区 11 个国家(保加利亚、克罗地亚、捷克、爱沙尼亚、匈牙利、拉脱维亚、立陶宛、波兰、罗马尼亚、塞尔维亚和斯洛文尼亚)HF 流行病学信息。该地区 HF 的患病率为 1.6-4.7%,发病率为每 1000 人年 3.1-6.0 人。由于这些国家 HF 管理方面发表的数据稀缺,我们还通过对代表 11 个国家的 11 名 HF 专家的两项调查收集了当地 HF 护理和管理实践的见解。基于文献综述和调查的综合结果,我们为每个国家创建了 HF 护理和管理简介,并为该地区开发了一个共同的 HF 患者路径。我们确定了优化 HF 护理的五个主要障碍:(i)缺乏流行病学数据,(ii)HF 意识低,(iii)缺乏国家 HF 策略,(iv)基础设施和系统差距,以及(v)获得新型 HF 治疗的机会有限。为了克服这些障碍,我们提出了以下改进途径:(i)建立区域和国家前瞻性 HF 登记处,以便系统地收集流行病学数据;(ii)为公众、患者、护理人员和医疗保健专业人员开展教育活动;(iii)建立正式的 HF 策略,以制定明确和可衡量的政策目标并支持预算规划;(iv)改善获得优质护理中心、多学科护理团队、诊断测试和远程医疗/远程监测的机会;(v)建立国家治疗监测计划,制定政策,确保将足够比例的医疗保健预算用于新型疗法。这些改进途径代表了通过减少该地区内和该地区与西欧之间 HF 护理的差异来改善中东欧和波罗的海地区 HF 患者结局的第一步。

相似文献

1
Heart failure care in the Central and Eastern Europe and Baltic region: status, barriers, and routes to improvement.中东欧和波罗的海地区的心力衰竭护理:现状、障碍和改善途径。
ESC Heart Fail. 2024 Aug;11(4):1861-1874. doi: 10.1002/ehf2.14687. Epub 2024 Mar 22.
2
Burden of varicella in Central and Eastern Europe: findings from a systematic literature review.中东欧水痘负担:系统文献回顾的结果。
Expert Rev Vaccines. 2019 Mar;18(3):281-293. doi: 10.1080/14760584.2019.1573145. Epub 2019 Feb 27.
3
Patterns and trends in human papillomavirus-related diseases in Central and Eastern Europe and Central Asia.中东北欧和中亚地区人乳头瘤病毒相关疾病的模式和趋势。
Vaccine. 2013 Dec 31;31 Suppl 7:H32-45. doi: 10.1016/j.vaccine.2013.02.071.
4
Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe.炎症性肠病的生物治疗:中东欧地区的可及性
World J Gastroenterol. 2015 Feb 14;21(6):1728-37. doi: 10.3748/wjg.v21.i6.1728.
5
Hospital reforms in 11 Central and Eastern European countries between 2008 and 2019: a comparative analysis.11 个中东欧国家 2008 年至 2019 年期间的医院改革:比较分析。
Health Policy. 2020 Apr;124(4):368-379. doi: 10.1016/j.healthpol.2020.02.003. Epub 2020 Feb 20.
6
Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe.人乳头瘤病毒流行率和型别分布、在中欧和东欧的宫颈癌筛查做法以及当前疫苗接种实施状况。
Vaccine. 2013 Dec 31;31 Suppl 7:H59-70. doi: 10.1016/j.vaccine.2013.03.029.
7
Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups.欧洲心脏病学会成员国心力衰竭管理组织:欧洲心脏病学会心力衰竭协会与心力衰竭国家学会/工作组合作调查。
Eur J Heart Fail. 2013 Sep;15(9):947-59. doi: 10.1093/eurjhf/hft092. Epub 2013 Jun 19.
8
Access to diagnostic imaging and radiotherapy technologies for patients with cancer in the Baltic countries, eastern Europe, central Asia, and the Caucasus: a comprehensive analysis.波罗的海国家、东欧、中亚和高加索地区癌症患者获得诊断成像和放射治疗技术的情况:综合分析。
Lancet Oncol. 2024 Nov;25(11):1487-1495. doi: 10.1016/S1470-2045(24)00452-2. Epub 2024 Oct 16.
9
The Heart Failure Association Atlas: rationale, objectives, and methods.心力衰竭协会图谱:原理、目标和方法。
Eur J Heart Fail. 2020 Apr;22(4):638-645. doi: 10.1002/ejhf.1768. Epub 2020 Mar 3.
10
Eastern Europe: pronatalist policies and private behavior.东欧:鼓励生育政策与个人行为
Popul Bull. 1982 Feb;36(6):1-49.

引用本文的文献

1
An overview of the association between socioeconomic deprivation and heart failure.社会经济剥夺与心力衰竭之间关联的概述。
Heart Fail Rev. 2025 Aug 12. doi: 10.1007/s10741-025-10550-x.
2
Gut microbiota's role in heart failure.肠道微生物群在心力衰竭中的作用。
Heart Fail Rev. 2025 Jul 9. doi: 10.1007/s10741-025-10543-w.
3
Effects of SGLT2 inhibitors on ion channels in heart failure: focus on the endothelium.钠-葡萄糖协同转运蛋白2抑制剂对心力衰竭中离子通道的影响:聚焦于内皮细胞。

本文引用的文献

1
SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials.钠-葡萄糖协同转运蛋白 2 抑制剂在心力衰竭患者中的应用:五项随机对照试验的综合荟萃分析。
Lancet. 2022 Sep 3;400(10354):757-767. doi: 10.1016/S0140-6736(22)01429-5. Epub 2022 Aug 27.
2
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC.2021 ESC 急性和慢性心力衰竭诊断和治疗指南:由欧洲心脏病学会(ESC)急性和慢性心力衰竭诊断和治疗工作组制定。特别感谢欧洲心脏病学会心力衰竭协会(HFA)的贡献。
Eur J Heart Fail. 2022 Jan;24(1):4-131. doi: 10.1002/ejhf.2333.
3
Basic Res Cardiol. 2025 May 14. doi: 10.1007/s00395-025-01115-y.
4
NT-proBNP for Heart Failure Screening in Primary Care in an Eastern European Country: What We Know and Proposed Steps.用于东欧国家初级保健中心力衰竭筛查的N末端B型利钠肽原:我们所了解的情况及建议措施
Epidemiologia (Basel). 2025 Jan 15;6(1):2. doi: 10.3390/epidemiologia6010002.
5
High-intensity care for GDMT titration.强化 GDMT 滴定治疗。
Heart Fail Rev. 2024 Sep;29(5):1065-1077. doi: 10.1007/s10741-024-10419-5. Epub 2024 Jul 22.
European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with the Heart Failure Association of the European Society of Cardiology.欧洲心脏病学会成人心力衰竭护理和结局质量指标。由心力衰竭质量指标工作组与欧洲心脏病学会心力衰竭协会合作制定。
Eur J Heart Fail. 2022 Jan;24(1):132-142. doi: 10.1002/ejhf.2371.
4
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.恩格列净治疗射血分数保留的心力衰竭。
N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27.
5
Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice.直接口服抗凝剂:从随机临床试验到真实世界临床实践
Front Pharmacol. 2021 May 26;12:684638. doi: 10.3389/fphar.2021.684638. eCollection 2021.
6
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.达格列净治疗射血分数保留和轻度降低的心衰:DELIVER 试验的原理和设计。
Eur J Heart Fail. 2021 Jul;23(7):1217-1225. doi: 10.1002/ejhf.2249. Epub 2021 Jun 9.
7
The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019.《心力衰竭协会图谱:心力衰竭流行病学和管理统计数据 2019》。
Eur J Heart Fail. 2021 Jun;23(6):906-914. doi: 10.1002/ejhf.2143. Epub 2021 Mar 13.
8
Excess deaths in people with cardiovascular diseases during the COVID-19 pandemic.心血管疾病患者在 COVID-19 大流行期间的超额死亡。
Eur J Prev Cardiol. 2021 Dec 20;28(14):1599-1609. doi: 10.1093/eurjpc/zwaa155.
9
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.索格列净治疗伴有近期恶化心力衰竭的糖尿病患者。
N Engl J Med. 2021 Jan 14;384(2):117-128. doi: 10.1056/NEJMoa2030183. Epub 2020 Nov 16.
10
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.恩格列净治疗心力衰竭的心血管和肾脏结局。
N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28.